Sangamo Therapeutics, Inc. - Common Stock (SGMO)

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in premarket.

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs.

The stock market experienced a significant downturn today, with the S&P 500 dropping nearly 5% to 5,396.52, marking its worst session since September 2022.

On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.

U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.